Cargando…
NRAS-mutant melanoma: current challenges and future prospect
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%–20% of melanomas. The NRAS-mutant subset of melanoma is more aggressive and associated with poorer outcomes, compared to...
Autores principales: | Muñoz-Couselo, Eva, Adelantado, Ester Zamora, Ortiz, Carolina, García, Jesús Soberino, Perez-Garcia, José |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5558581/ https://www.ncbi.nlm.nih.gov/pubmed/28860801 http://dx.doi.org/10.2147/OTT.S117121 |
Ejemplares similares
-
Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma
por: Garcia-Alvarez, Alejandro, et al.
Publicado: (2021) -
NRAS mutant melanoma – undrugable?
por: Posch, Christian, et al.
Publicado: (2013) -
MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018) -
Playing POLO-like kinase in NRAS mutant melanoma
por: Chen, Hsin-Yi, et al.
Publicado: (2015) -
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)